Abstract
Deferasirox [Exjade, ICL 670], an oral once-daily iron chelator, was shown to be effective in the treatment of iron overload in both adults and children in studies presented at the 46th Annual Meeting of the American Society of Hematology (ASH) [San Diego, US; December 2004]. In a phase III study involving almost 600 patients with thalassaemia, deferasirox produced dose-dependent reductions in liver iron concentration (LIC), to levels comparable to those observed with the current standard therapy, deferoxamine. A phase II study showed that deferasirox reduced LIC in patients with myelodysplastic syndromes and Diamond-Blackfan syndrome, and in patients with thalassaemia who had inadequate chelation with deferoxamine.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
